These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 19401349

  • 1. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, Nordenskjöld B, Stål O.
    Clin Cancer Res; 2009 May 15; 15(10):3610-6. PubMed ID: 19401349
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
    Oduwole OO, Li Y, Isomaa VV, Mäntyniemi A, Pulkka AE, Soini Y, Vihko PT.
    Cancer Res; 2004 Oct 15; 64(20):7604-9. PubMed ID: 15492288
    [Abstract] [Full Text] [Related]

  • 4. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
    Jansson AK, Gunnarsson C, Cohen M, Sivik T, Stål O.
    Cancer Res; 2006 Dec 01; 66(23):11471-7. PubMed ID: 17145895
    [Abstract] [Full Text] [Related]

  • 5. Expression of COX-2 and steroid converting enzymes in breast cancer.
    Gunnarsson C, Jansson A, Holmlund B, Ferraud L, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O.
    Oncol Rep; 2006 Aug 01; 16(2):219-24. PubMed ID: 16820896
    [Abstract] [Full Text] [Related]

  • 6. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2009 Sep 15; 15(18):5888-94. PubMed ID: 19723645
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
    J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550
    [Abstract] [Full Text] [Related]

  • 10. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G.
    J Natl Cancer Inst; 2006 May 17; 98(10):671-80. PubMed ID: 16705121
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2007 Sep 01; 25(25):3846-52. PubMed ID: 17679725
    [Abstract] [Full Text] [Related]

  • 14. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.
    Cancer; 2008 Apr 01; 112(7):1437-44. PubMed ID: 18286526
    [Abstract] [Full Text] [Related]

  • 15. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.
    Larsson AM, Jirström K, Fredlund E, Nilsson S, Rydén L, Landberg G, Påhlman S.
    Clin Cancer Res; 2009 Sep 01; 15(17):5552-9. PubMed ID: 19706814
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
    Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström K.
    Clin Cancer Res; 2006 Aug 01; 12(15):4614-8. PubMed ID: 16899609
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.